Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bio Green Med Solution ( (BGMS) ) has shared an update.
On September 11, 2025, Bio Green Med Solution received a notice from Nasdaq indicating that its 6% Convertible Exchangeable Preferred Stock no longer meets the minimum Market Value of Publicly Held Shares requirement of $1 million. The company has until March 10, 2026, to regain compliance, during which time the stock will continue to trade. Failure to meet the requirement by the deadline could result in delisting, but the company is actively monitoring the situation and considering options to address the issue.
Spark’s Take on BGMS Stock
According to Spark, TipRanks’ AI Analyst, BGMS is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on BGMS stock, click here.
More about Bio Green Med Solution
Bio Green Med Solution, Inc., formerly known as Cyclacel Pharmaceuticals, Inc., operates in the pharmaceutical industry and is focused on developing medical solutions.
Average Trading Volume: 1,863,750
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.73M
See more insights into BGMS stock on TipRanks’ Stock Analysis page.